Selected article for: "blood brain and immune response"

Author: Chiu, Simon S.; Terpstra, Kristen; Woodbury-Farina, Michel; Badmaev, Vladimir; Varghese, Josh; Raheb, Hana; Lui, Ed; Cernovsky, Zack; Bureau, Yves; Husni, Mariwan; Copen, John; Shad, Mujeeb; Carriere, Autumn; Khazaeipool, Zahra; Sieffien, Weam; Henein, Marina; Casola, Brendan; Shrivastava, Siddhansh
Title: Transforming curry extract-spice to liposome-based curcumin: lipocurc to restore and boost brain health in COVID-19 syndrome
  • Cord-id: v6zrt49l
  • Document date: 2020_11_13
  • ID: v6zrt49l
    Snippet: Despite the devastating impact of COVID-19 on all domains of health, very few studies focus on epigenetics-based approaches to target both the viral-host immune responses and central nervous system involvement in COVID-19. Hospitalized COVID-19 patients experience a wide array of neurological symptoms ranging from convulsions to strokelike syndrome and anosmia. None of the pipeline antiviral drugs has been shown to penetrate the blood-brain barrier to exert neurotrophic actions to counteract the
    Document: Despite the devastating impact of COVID-19 on all domains of health, very few studies focus on epigenetics-based approaches to target both the viral-host immune responses and central nervous system involvement in COVID-19. Hospitalized COVID-19 patients experience a wide array of neurological symptoms ranging from convulsions to strokelike syndrome and anosmia. None of the pipeline antiviral drugs has been shown to penetrate the blood-brain barrier to exert neurotrophic actions to counteract the COVID-19 damage to the brain. We have identified curcumin extracted from Turmeric (Curcuma longa) exhibiting dual properties: to disrupt viral attachment and hijacking host-viral immune response and to target epigenetics pathway regulating oxidative stress and inflammation responses underlying COVID-19 syndrome. We recruit nanotechnology to formulate liposome-based curcumin: Lipocurc, and completed Phase I study showing very favorable safety and efficacy in Parkinson disease model. We propose to translate the findings to COVID-19 syndrome and exploit the antidepressant and cognitive enhancing properties to accelerate recovery from COVID-19 through navigating brain pathways regulating mood, behavioral control, and cognition within the context of acute and postacute COVID-19 syndrome.

    Search related documents:
    Co phrase search for related documents
    • academia industry and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • academia industry and acute respiratory distress syndrome: 1
    • academia industry and acute syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • academia industry and acute treatment: 1
    • academia industry and long lasting: 1, 2
    • academic industry and acute phase: 1, 2
    • academic industry and acute respiratory: 1, 2, 3, 4
    • academic industry and acute respiratory distress syndrome: 1
    • academic industry and acute syndrome: 1, 2, 3, 4, 5
    • academic industry and acute treatment: 1, 2, 3, 4